Building Smarter Therapeutics with VHH Bolt-Ons Single-domain antibodies derived from camelids, also known as VHHs or nanobodies, are highly adaptable binding domains widely used in protein engineering. They were pioneered by Raymond Hamers at Vrije Universiteit...
CIS Display™ vs. Phage Display: Choosing the Right Fit for VHH or Peptide Discovery Choosing the right display technology is a critical decision in therapeutic and diagnostic discovery procedures. This article compares CIS Display™ with Phage Display, focusing on...
Building the next generation of precision oncology medicines Biologic therapies have reshaped oncology, but they come with real limitations. Traditional monoclonal antibodies are large, complex molecules that can struggle with tumor penetration, slow development...
Comparing Risk in Synthetic vs Immune-based Discovery: Why Synthetic VHH Antibodies are the Future of Antibody Discovery The biotech and pharma industies thrive on a balance of caution and innovation, carefully managing risks, while pushing the boundaries. In VHH...
VHH Humanisation Unlike conventional IgG antibodies from humans or mice, VHHs (also known as nanobodies) are composed solely of the single variable domain of a heavy chain. Originally derived from llamas, VHH antibody humanisation is often required. Here we compare...
The golden age of bi-specific antibodies is here Bi-specific antibodies (BsAbs) – antibodies that can recognise two different epitopes on either the same or different antigens – have been around for a long time. However, in the past few years we’ve seen a...
